Literature DB >> 17709472

Antiprion activity of cholesterol esterification modulators: a comparative study using ex vivo sheep fibroblasts and lymphocytes and mouse neuroblastoma cell lines.

Alessandra Pani1, Claudia Norfo, Claudia Abete, Claudia Mulas, Marirosa Putzolu, Sergio Laconi, Christina Doriana Orrù, M Dolores Cannas, Sarah Vascellari, Paolo La Colla, Sandra Dessì.   

Abstract

Our studies on the role of cholesterol homeostasis in the pathogenesis of scrapie revealed abnormal accumulation of cholesterol esters in ex vivo peripheral blood mononuclear cells (PBMCs) and skin fibroblasts from healthy and scrapie-affected sheep carrying a scrapie-susceptible genotype compared to sheep with a resistant genotype. Similar alterations were observed in mouse neuroblastoma N2a cell lines persistently infected with mouse-adapted 22L and RML strains of scrapie that showed up to threefold-higher cholesterol ester levels than parental N2a cells. We now report that proteinase K-resistant prion protein (PrPres)-producing cell populations of subclones from scrapie-infected cell lines were characterized by higher cholesterol ester levels than clone populations not producing PrPres. Treatments with a number of drugs known to interfere with different steps of cholesterol metabolism strongly reduced the accumulation of cholesterol esters in ex vivo PBMCs and skin fibroblasts from scrapie-affected sheep but had significantly less or no effect in their respective scrapie-resistant or uninfected counterparts. In scrapie-infected N2a cells, inhibition of cholesterol esters was associated with selective antiprion activity. Effective antiprion concentrations of cholesterol modulators (50% effective concentration [EC(50)] range, 1.4 to 40 microM) were comparable to those of antiprion reference compounds (EC(50) range, 0.6 to 10 microM). These data confirm our hypothesis that abnormal accumulation of cholesterol esters may represent a biological marker of susceptibility to prion infection/replication and a novel molecular target of potential clinical importance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17709472      PMCID: PMC2151450          DOI: 10.1128/AAC.00524-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments.

Authors:  Ralf Klingenstein; Stefan Löber; Pekka Kujala; Susan Godsave; S Rutger Leliveld; Peter Gmeiner; Peter J Peters; Carsten Korth
Journal:  J Neurochem       Date:  2006-06-02       Impact factor: 5.372

Review 2.  Developing therapeutics for the diseases of protein misfolding.

Authors:  Barnaby C H May; Cedric Govaerts; Fred E Cohen
Journal:  Neurology       Date:  2006-01-24       Impact factor: 9.910

3.  The prototypical inhibitor of cholesterol esterification, Sah 58-035 [3-[decyldimethylsilyl]-n-[2-(4-methylphenyl)-1-phenylethyl]propanamide], is an agonist of estrogen receptors.

Authors:  Philippe de Medina; Nadia Boubekeur; Patrick Balaguer; Gilles Favre; Sandrine Silvente-Poirot; Marc Poirot
Journal:  J Pharmacol Exp Ther       Date:  2006-07-11       Impact factor: 4.030

4.  The prion protein requires cholesterol for cell surface localization.

Authors:  Sabine Gilch; Claudia Kehler; Hermann M Schätzl
Journal:  Mol Cell Neurosci       Date:  2005-11-08       Impact factor: 4.314

Review 5.  The intriguing prion disorders.

Authors:  K Abid; C Soto
Journal:  Cell Mol Life Sci       Date:  2006-10       Impact factor: 9.261

6.  Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt-Jakob disease.

Authors:  I R Whittle; R S G Knight; R G Will
Journal:  Acta Neurochir (Wien)       Date:  2006-04-07       Impact factor: 2.216

7.  Knockdown of ACAT-1 reduces amyloidogenic processing of APP.

Authors:  Henri J Huttunen; Christopher Greco; Dora M Kovacs
Journal:  FEBS Lett       Date:  2007-03-30       Impact factor: 4.124

Review 8.  A systematic review of prion therapeutics in experimental models.

Authors:  Clare R Trevitt; John Collinge
Journal:  Brain       Date:  2006-07-01       Impact factor: 13.501

9.  Kuru in the 21st century--an acquired human prion disease with very long incubation periods.

Authors:  John Collinge; Jerome Whitfield; Edward McKintosh; John Beck; Simon Mead; Dafydd J Thomas; Michael P Alpers
Journal:  Lancet       Date:  2006-06-24       Impact factor: 79.321

10.  Accumulation of pathological prion protein PrPSc in the skin of animals with experimental and natural scrapie.

Authors:  Achim Thomzig; Walter Schulz-Schaeffer; Arne Wrede; Wilhelm Wemheuer; Bertram Brenig; Christine Kratzel; Karin Lemmer; Michael Beekes
Journal:  PLoS Pathog       Date:  2007-05-25       Impact factor: 6.823

View more
  10 in total

1.  Efficacy and mechanism of a glycoside compound inhibiting abnormal prion protein formation in prion-infected cells: implications of interferon and phosphodiesterase 4D-interacting protein.

Authors:  Keiko Nishizawa; Ayumi Oguma; Maki Kawata; Yuji Sakasegawa; Kenta Teruya; Katsumi Doh-ura
Journal:  J Virol       Date:  2014-01-22       Impact factor: 5.103

2.  Melanin or a Melanin-Like Substance Interacts with the N-Terminal Portion of Prion Protein and Inhibits Abnormal Prion Protein Formation in Prion-Infected Cells.

Authors:  Taichi Hamanaka; Keiko Nishizawa; Yuji Sakasegawa; Ayumi Oguma; Kenta Teruya; Hiroshi Kurahashi; Hideyuki Hara; Suehiro Sakaguchi; Katsumi Doh-Ura
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

3.  Comparison of hematological and biochemical parameters in sheep naturally and persistently infected with a border disease virus.

Authors:  Serkal Gazyağci; Ahmet Kursat Azkur; Osman Cağlayan
Journal:  Trop Anim Health Prod       Date:  2010-11-21       Impact factor: 1.559

Review 4.  Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions.

Authors:  Byron Caughey; Gerald S Baron; Bruce Chesebro; Martin Jeffrey
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

Review 5.  Recent advances in prion chemotherapeutics.

Authors:  Valerie L Sim; Byron Caughey
Journal:  Infect Disord Drug Targets       Date:  2009-02

6.  Accumulation and aberrant composition of cholesteryl esters in Scrapie-infected N2a cells and C57BL/6 mouse brains.

Authors:  Sarah Vascellari; Sebastiano Banni; Claudia Vacca; Vito Vetrugno; Franco Cardone; Michele A Di Bari; Paolo La Colla; Alessandra Pani
Journal:  Lipids Health Dis       Date:  2011-08-04       Impact factor: 3.876

Review 7.  Cholesterol balance in prion diseases and Alzheimer's disease.

Authors:  Samia Hannaoui; Su Yeon Shim; Yo Ching Cheng; Erica Corda; Sabine Gilch
Journal:  Viruses       Date:  2014-11-20       Impact factor: 5.048

8.  Cholesterol homeostasis: a key to prevent or slow down neurodegeneration.

Authors:  Laura Anchisi; Sandra Dessì; Alessandra Pani; Antonella Mandas
Journal:  Front Physiol       Date:  2013-01-04       Impact factor: 4.566

9.  Discovery of a novel, monocationic, small-molecule inhibitor of scrapie prion accumulation in cultured sheep microglia and Rov cells.

Authors:  James B Stanton; David A Schneider; Kelcey D Dinkel; Bethany F Balmer; Timothy V Baszler; Bruce A Mathison; David W Boykin; Arvind Kumar
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

10.  Serum Biochemistry of Lumpy Skin Disease Virus-Infected Cattle.

Authors:  Murat Şevik; Oğuzhan Avci; Müge Doğan; Ömer Barış İnce
Journal:  Biomed Res Int       Date:  2016-05-12       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.